Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous dendritic cells infected with Fowlpox-CEA-TRICOM
- Development stage
- Unknown
- Lead developer
- Michael Morse
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
Autologous dendritic cells infected with Fowlpox-CEA-TRICOM is an experimental active immunotherapy developed by Michael Morse, MD, at Duke University. This cell-based vaccine involves harvesting a patient's own dendritic cells and infecting them ex vivo with a recombinant fowlpox virus vector. This vector is engineered to express a modified version of the carcinoembryonic antigen (CEA-6D) along with a triad of costimulatory molecules (TRICOM) consisting of B7-1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58). The modified dendritic cells are then re-infused into the patient to present the CEA antigen to the immune system. The inclusion of TRICOM is intended to enhance the activation and proliferation of CEA-specific T cells, thereby mounting a more robust immune response against CEA-expressing malignancies such as colorectal, pancreatic, and breast cancers.
- Other names
- Dendritic cells loaded with TRICOM-CEA(6D)CEA-6D expressing Fowlpox-Tricom infected dendritic cellsCEA6D expressing Fowlpox-Tricom infected dendritic cellsCEA 6D expressing Fowlpox-Tricom infected dendritic cells
02
Targets
CD80 (T-lymphocyte activation antigen CD80)ICAM1 (Intercellular Adhesion Molecule 1)CD58 (Leukocyte function-associated antigen 3)
Beyond the preview
Go deeper on Autologous dendritic cells infected with Fowlpox-CEA-TRICOM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous dendritic cells infected with Fowlpox-CEA-TRICOM.